|
US2020048208A1
|
|
TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
|
|
US2017115308A1
|
|
Assay to measure efficacy of cdk8/19 inhibitors
|
|
TN2014000328A1
|
|
Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
|
|
WO2014134169A1
|
|
Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
|
|
US2014199708A1
|
|
Cell-based methods for measuring activity of a protein inhibitor
|
|
WO2014089450A1
|
|
Specific inhibitors of cdk3
|
|
US2014378683A1
|
|
CDKI pathway inhibitors and uses thereof
|
|
US2014038958A1
|
|
CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
|
|
US2010190807A1
|
|
CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
|
|
US2009281129A1
|
|
Cdki pathway inhibitors and uses thereof
|
|
AU2007249762A1
|
|
Identification of CDKI pathway inhibitors
|
|
CA2652339A1
|
|
Cdki pathway inhibitors as selective inhibitors of tumor cell growth
|
|
CA2594814A1
|
|
High-content screening for drugs against cancer and age-related diseases
|
